CClinicalTrials.gg
CompletedNCT07443839Updated Jul 16, 2026

Oncology Legal Navigation Study

An interventional study of oncology legal navigation services in Financial Stress and Oncology Patients, sponsored by Jean Edward. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Jean Edward · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2025, registered Feb 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The overall objective of this study is to implement a sustainable oncology legal navigation program that will provide direct legal navigation services to help patients and caregivers overcome legal barriers to care in order to reduce cancer-related financial toxicity (FT) and improve health-related quality of life (QOL) among patients/caregivers.

02

Conditions studied

  • Financial Stress
  • Oncology Patients

Browse trials for

Keywords

  • Financial toxicity
  • Hardship
  • Cost conversations
03

In context

Financial Stress

93 studies on the registry are indexed under Financial Stress; 32 are open to participants now.

This study's enrollment of 70 is below the median of 124 across 55 interventional studies indexed under Financial Stress.

Browse Financial Stress studies →

Lead sponsor

Jean Edward is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • receiving or have received services at the Markey Cancer Center, University of Kentucky
  • patient with cancer diagnosis
  • caregiver of patient with cancer diagnosis
  • 18 years or older
  • facing legal barriers to care

Exclusion criteria

Exclusion Criteria:

  • Unable to provide consent
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Adult patient or caregiver of patient with cancer diagnosis

    legal navigation program in oncology care

    Other: oncology legal navigation services

Interventions

  • Otheroncology legal navigation services

    Participants receive direct legal assistance/navigation followed by consultation, and assistance with legal issues related to health/social benefits, housing, employment/education, planning ahead, and family law

06

What researchers measure

Primary outcomes

  1. Number of participants enrolled

    Feasibility was defined as 60% or higher enrolled participant retention and resolution of financial or legal issue (based on existing oncology financial navigation studies)

    Time frame: 12 months

  2. Acceptability assessed by 5-item survey

    Acceptability is measured using a 5 item post-intervention survey of relevance, helpfulness, convenience, recommendation to others, and value. Ratings on a scale from 0 to 10 where a higher score means greater acceptability

    Time frame: Post intervention at 12 months

  3. Change in Total Financial Toxicity

    Measured using the COmprehensive Score for financial Toxicity (COST) tool, a measure that describes the financial distress experienced by cancer patients. Scores range from 0-44 with a higher score representing better financial well-being.

    Time frame: Baseline and post intervention,up to 12 months

  4. Change in Participant Quality of Life (physical and mental)

    Measured using the 10-item PROMIS® (Patient-Reported Outcomes Measurement Information System) Parent Proxy Global Health scale. A 7-item summary assessment of a child's self-reported health with higher scores representing better quality of life. Values range from 7-35, with higher scores representing better health.

    Time frame: Baseline and post intervention, up to 12 months

  5. Change in Participant Quality of Life (Depression)

    Measured using the 6-item Patient-Reported Outcomes Measurement Information System PROMIS® Depression Short Form. Scores range from 6 to 30. Higher scores indicate more of the construct being measured.

    Time frame: Baseline and post intervention, up to 12 months

  6. Change in Participant Quality of Life (Anxiety)

    Measured using the 4-item Patient-Reported Outcomes Measurement Information System PROMIS® Anxiety short form. Scores range from 4 to 20. Higher scores indicate more of the construct being measured.

    Time frame: Baseline and post intervention, up to 12 months

  7. Resolution of legal Issue

    Number of participants that resolved a legal or financial case as a result of the intervention

    Time frame: 12 months

Secondary outcomes

  1. Number of Participants Receiving Financial Benefit

    financial benefit defined as economic hardship avoided or decreased public/government income

    Time frame: 12 months

  2. Single Item Literacy Screener (SILS)

    Single Item Literacy Screener (SILS); SILS asks "How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy?" with answer options: "Never, Rarely, Sometimes, Often Always". Higher scores indicate lower health literacy.

    Time frame: Baseline and post-intervention at 12 months

  3. Health Insurance Literacy (HIL)

    Single Item Health Insurance Literacy Scale; "Did you ever have a problem understanding health insurance or medical bills related to your cancer, its treatment, or the lasting effects of that treatment?" Those who answered "Yes" were coded as having inadequate health insurance literacy and those who responded "No" were coded as having adequate HIL.

    Time frame: Baseline and post-intervention at 12 months

07

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40506, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443839
Lead sponsor
Jean Edward
Collaborators
University of California, Davis
Responsible party
Jean Edward (Associate Professor, University of Kentucky) — Sponsor-investigator
First posted
Mar 2, 2026
Start date
Mar 24, 2025
Primary completion
Jun 15, 2026
Completion
Jun 15, 2026
Last update
Jul 16, 2026

Study contacts

Jean Edward, PhD, RN
principal investigator · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion